First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Author:

Liu Tianshu1ORCID,Bai Yuxian2,Lin Xiaoyan3,Li Wei4,Wang Jufeng5,Zhang Xiaochun6,Pan Hongming7,Bai Chunmei8ORCID,Bai Li9,Cheng Ying10,Zhang Jingdong11ORCID,Zhong Haijun12,Ba Yi13,Hu Wenwei14,Xu Ruihua15ORCID,Guo Weijian16,Qin Shukui17ORCID,Yang Nong18,Lu Jianwei19,Shitara Kohei20,Lei Ming21,Li Mingshun21,Bao Nicole21,Chen Tian21,Shen Lin22ORCID

Affiliation:

1. Zhongshan Hospital Fudan University Shanghai China

2. Herbin Medical University Heilongjiang China

3. Fujian Medical University Union Hospital Fuzhou China

4. The First Hospital of Jilin University Changchun China

5. The Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China

6. The Affiliated Hospital of Qingdao University Qingdao China

7. Sir Run Run Shaw Hospital Hangzhou China

8. Peking Union Medical College Hospital Beijing China

9. China P.L.A. General Hospital (301 Hospital) Beijing China

10. Jilin Cancer Hospital Changchun China

11. Liaoning Cancer Hospital and Institute Shenyang China

12. Zhejiang Cancer Hospital Hangzhou China

13. Tianjin Medical University Cancer Institute and Hospital Tianjin China

14. The First People's Hospital of Changzhou Changzhou China

15. Medical Oncology Cancer Center Sun Yat‐Sen University Guangzhou China

16. Fudan University Shanghai Cancer Center Shanghai China

17. Eastern Theater General Hospital QinHuai District Medical Area China

18. Hunan Cancer Hospital Changsha Shi China

19. Jiangsu Cancer Hospital Nanjing China

20. National Cancer Center Hospital East Kashiwa Japan

21. Bristol Myers Squibb Princeton New Jersey USA

22. Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Peking University Cancer Hospital and Institute Beijing China

Funder

Bristol Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. International Agency for Research on Cancer2020.China cancer incidence and mortality 2020: GLOBOCAN fact sheet 2020.

3. Gastric adenocarcinoma

4. Global burden of oesophageal and gastric cancer by histology and subsite in 2018

5. National Comprehensive Cancer Network.Gastric cancer (version 3.2021).https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3